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Abstract.  The present study was undertaken to deter- 
mine the relationship between the hyaluronate receptor 
and CD44 (H-CAM), cell-surface glycoproteins of 
similar molecular weights that have been implicated in 
cell adhesion.  In initial experiments,  a panel of mono- 
clonal antibodies directed against CD44 were tested 
for their ability to cross react with the hyaluronate 
receptor.  These antibodies immunoprecipitated 
[3H]hyaluronate binding activity from detergent ex- 
tracts of both mouse and human cells, indicating that 
the hyaluronate receptor is identical to CD44.  In addi- 
tion, one of these antibodies (KM-201 to mouse 
CD44) directly blocked the binding of labeled 
hyaluronate to the receptor and inhibited hyaluronate 
dependent aggregation of SV-3T3 cells. CD44 has also 
been implicated in lymphocyte binding to high en- 
dothelial venules during  lymphocyte homing.  Interest- 
ingly,  the monoclonal antibody Hermes-3, which 
blocks lymphocyte binding to the high endothelial 
venules of mucosal lymphoid tissue, had no effect on 
the binding of labeled hyaluronate.  Furthermore,  the 
binding of lymphoeytes to high endothelial cells of 
lymph nodes and mucosal lymphoid tissue was not 
significantly affected by treatment with agents that 
block the binding of hyaluronate (hyaluronidase,  excess 
hyaluronate and specific antibodies).  Thus,  CD44 ap- 
pears to have at least two distinct functional domains, 
one for binding hyaluronate and another involved in 
interactions with mucosal high endothelial venules. 
T  H~. hyaluronate receptor is a cell surface glycoprotein 
of 85 kD that is responsible for the adhesion  of cells 
to hyaiuronate and chondroitin  sulfate in the extracel- 
lular matrix (36). This receptor is present on a wide variety 
of cells including  most macrophages,  epithelial  ceils,  and 
some neurons (1, 10, 36). In the case of epithelia,  it is prefer- 
entially expressed on actively proliferating cells as compared 
to their  nonproliferating  counterparts  (1). In addition  the 
hyaluronate receptor appears to be associated with actin fila- 
ments  (20),  a  characteristic  that  may allow  it to mediate 
transmembrane  signaling  between the extracellular  matrix 
and the cytoskeleton. 
Another membrane glycoprotein involved in cell adhesion 
has been described that is similar to the hyaluronate receptor 
with respect to molecular weight,  tissue distribution  (6, 28) 
and association with actin filaments (15, 19). This glycopro- 
tein (or set of closely related glycoproteins)  has been studied 
by a  number  of different  laboratories,  and  has  been re- 
ferred to variously as Pgp-1 (13), Ly-24 (22), ECMRIII (4), 
gp90  ~m" (3), and H-CAM (28). However, subsequent stud- 
ies have revealed  that these proteins are in fact closely re- 
lated or identical to each other (7, 22, 27, 29, 32), and repre- 
sent CD44, one of the cluster of differentiation  antigens  in 
leukocytes (12). The CIM4 protein has been shown to medi- 
ate  the  interaction  between  lymphocytes  and  high  en- 
dothelial cells during lymphocyte homing (16, 17). It has also 
been implicated  in a number of other lymphocyte adhesion 
events,  including  interactions  of T-cells  with erythrocytes 
and monocytes (12). And finally, CD44 appears to play a 
role in the interaction  between the hemopoietic and stromal 
cells of the bone marrow,  which may involve hyaluronate 
(24, 25). 
The  connection  between the  hyaluronate  receptor  and 
CD44 was initially suggested by the studies Goldstein et al. 
(9) and Stamenkovic et al. (30). These researchers indepen- 
dently reported that the extracellular  domain of CD44 is ho- 
mologous to the hyaiuronate binding  region of the link pro- 
tein of cartilage.  This finding suggested that CD44 may be 
able to bind hyaluronate,  and  thus  closely resembles the 
receptor. 
The present study was undertaken to define more clearly 
the relationship  between the hyaluronate  receptor and the 
CD44 family of molecules.  For this,  we first examined the 
hyaluronate  receptor  to  determine  whether  it  resembles 
CD44 with respect to both isoelectric point and presence of 
phosphate linkages.  Secondly, we tested a variety of mAbs 
against CD44 to determine whether they cross react with the 
hyaluronate  receptor.  The results of this study indicate that 
the hyaluronate  receptor is indeed identical  to CD44. 
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mAb  Antigenic specificity  Biological effect 
K-3  Hamster hyaluronate  Blocks binding of hyaluronate to receptor (35). 
receptor 
Mel-14  Mouse lymph node 
homing receptor (Mel-14) 
KM-201  Mouse CD44  (Pgp-1) 
Hermes-1 
H2 -7 
H2-280 
Hermes-3 
BU52 
J173 
Human CD44  (H-CAM) 
Human CD44  (H-CAM) 
Human CD44  (H-CAM) 
Human CD44 (H-CAM) 
Human CD44 
Human CD44  (Pgp-l) 
Blocks adhesion of lymphocytes to high 
endothelial cells of peripheral lymph node (2). 
Blocks adhesion between lymphocytes and 
stromal cells (23). 
None known (26). 
None known (26). 
None known (26). 
Blocks adhesion of lymphocytes to endothelial 
cells of mucosal lymphoid tissue (16). 
None known. 
None known (29). 
Materials and Methods 
Cell Lines and Culture Conditions 
The  SV-3T3  (Swiss  mouse)  and  the  BHK cell  lines  were  grown  and  cultured 
as  previously  described  (37).  The HCV-29T cell  line  (invasive  human blad- 
der  carcinoma), which expresses the hyainronate receptor (26), was kindly 
donated by Dr. Warren Knudson (Rush Medical Center, Chicago,  IL). The 
cells were cultured in 10% Nu-Serum (Collaborative Research,  Lexington, 
MA), 90% DME containing 100 U/ml penicillin, and 100 ~g/ml of strep- 
tomycin in an atmosphere of 5% CO2, 95 % air. For the hyaiuronate bind- 
ing assay, the cells were cultured for 1 d in serum-free medium before har- 
vesting to remove the last traces of serum. 
Antibodies 
A list of the various  mAbs used in this study is shown in Table I. K-3, a 
mouse mAb against the hyaiuronate  receptor from hamster cells was iso- 
lated  from ascites fluid  by chromatography on  a  protein A-Sepharose 
column  (I  I).  The  KM-201 mAb (rat  IgG) against  mouse  CD44 was  isolated 
and purified  by ion-exchange  chromatography (24).  Mouse mAbs against 
the  human  CD44 molecule  include  the  Hermes series  (Hermes-l,  H2-7,  H2- 
280,  and Hermes-3) (16,  17,  28),  the  BU52 (purchased  in  a purified  form 
from  the  Binding  Site,  San  Dingo,  CA),  and  J173  which  was  kindly  donated 
by Dr. John M. Pesando (the  Biomembrane Institute,  Seattle,  WA). This 
last  mAb was  used  directly  in  the  ascites  form.  Control  antibodies  consisted 
oflgG  purified  from  nonimmune mouse  serum  (II),  and  the  rat  mAb Mel-14 
(American Type Culture Collection,  Rockville,  MD) which is directed 
against  a homing receptor  of  90 kD distinct  from CD44 (3). 
The  mAbs were  coupled  to  biotin  using  the  method  of  Updyke  and  Nicol- 
son (41)  except  that  sulfosuccinmidyl  6-Coiotinamido)  bexanoate (Pierce 
Chemical  Co., Rockford, IL) was  substituted  for the sulfosuccini- 
modobiotin. 
Electrophoresis and Western Blotting 
For labeling proteins with [32p]PO4-3, confluent cultures of BHK cells 
were grown in serum-free medium for 1 d, and then incubated for 1 h in 
a modified Krebs Ringer's solution without phosphate to deplete the intra- 
cellular pools of ATP (8). The medium was then changed to one containing 
20 ~Ci [32p]PO4-3/ml and incubated for an additional hour. The cells were 
washed, extracted, and dissolved  in a urea sample buffer containing a  1:3 
mixture of 3-10 and 5-7 amphulytes, (Bio-Rad Laboratories, Richmond, 
CA). The sample was processed for two-dimensional  electrophoresis,  using 
a 10% SDS polyacrylamide gel under nonreducing conditions for the sec- 
ond dimension.  The resulting gel  was  electrophoreticaily  blotted onto 
nitrocellulose,  which was blocked in 5 % nonfat milk, and then immuno- 
stained for the hyniuronate  receptor with biotinylated K-3 mAb as previ- 
ously described (11). The blot was subsequently processed for autoradiogra- 
phy using Fuxtak X Omat film. 
Immunoprecipitation 
The procedure for immunoprecipitation  was based upon that of Updyke and 
Nicolson (41). Cultured cells (SV-3T3 for mouse,  HCV-29T for human) 
were extracted in 0.1% Na deexycholate,  0.5 M NaCl, 0.02 M Tris, pH 8.0 
(DOC buffer),  l and then homogenized with a polywon (Brinkmann Instru- 
ments, Westbury,  NY).  Nonspecifically  binding material was removed by 
incubating 2-ml aliquots of the extract for 30 rain with 50 ~l of a 50% slurry 
of stmptavidin-ngarose  (Pierce Chemical Co., Rockford,  IL), followed by 
centrifugation at 9,000 g for l0 s in a Microfuge B (Beckman Instruments, 
Inc., Paio Alto, CA). Next, the various biotinylated mAbs were added to 
aliquots  of the supernatant. After incubating for a minimum of 2 h on a 
rotating table, stmptavidin-ngarose (0.2 mi/ml extract) was added to each 
sample and further incubated for 1 h. The samples were then centrifuged 
(9000 g,  10 s), and the superuatants were collected for further testing. 
To determine the amount of biotinylated antibody removed by this proce- 
dure, samples of the extracts both before and after the addition of the im- 
mobilized streptavidin were serially diluted and blotted onto nitrocellulose 
using a dot blot apparatus (Bio-Rad Laboratories). The blot was then in- 
cubated with streptavidin coupled to horseradish peroxidase  and followed 
by a substrate consisting of H202 and 3-amino-9 ethyl carbazole (11). The 
relative amounts of the biotinylated protein could be estimated from the in- 
tensity of the staining. In each case, at least 80% of  the biotinylated  antibody 
was removed by the procedure described above. 
Hyaluronate Binding Assay 
The hyaluronate binding assay was a miniaturized version of that described 
previously  (38). In some experiments,  the cell extracts were preincubated 
with the various mAbs at 22"C for 30 min before the assay. Samples of the 
cell extracts in DOC buffer (0.25 ml final volume) were mixed with 1 ~tg 
[3H]hyaiuronate (Batch 1, 7.7  x  104 cpm/~g; Batch 2, 9.8 ×  104 cpm//~g) 
at  room  temperature.  After  30  rain,  an  equal  volume  of  saturated 
(NH4)2SO4 was added to each sample followed by 25/d of nonfat milk that 
acts as a carrier.  The samples were then centrifuged (9,000 g, 5 min), and 
the tubes containing the precipitates were washed 2 times with 50% satu- 
rated  (NI'Lt)2SO4. The  precipitates  were  resuspended  in  water  and 
processed for scintillation counting.  The background level of binding was 
determined by including 100 t~g of noulabeled hyaiuronate in the assay. The 
results are expressed  in terms of specific binding in which the background 
levels of binding have been subtracted. Since the specific binding depends 
upon the particular preparation of [3H]hyaluronate  and cell extract,  the 
level of binding will vary from experiment to experiment. 
Partial Purification of the Hyaluronate Receptor 
The hyaiuronate receptor was partinlly purified by hydroxylapatite and mo- 
lecular sieve chromatography as described previously  (39). HCV-29T cells 
were extracted in 0.5% Na deoxycholate,  0.01 M NaItPO4, pH 8.0, and ap- 
plied to an 8.5 ×  1.5-cm column of hydroxylapatite,  which was eluted with 
a  linear gradient of 0.1% Na deoxychulate,  0.01 M  NaHPO4  to 0.3  M 
NaHPO4,  pH 8.0. The fractions containing [3H]hyniuronate binding activ- 
ity were pooled and concentrated  on a pressure  filter  cell  (YM-10 filter; 
1. Abbreviations used in this paper: CMF-PBS,  calcium- and magnesium- 
free PBS; DOC buffer, 0.1% Na deoxycholate,  0.5 M NaC1, 0.02 M Tris, 
pH 8.0. 
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and phosphorylation of  the hy- 
aluronate receptor.  Confluem 
BHK ceils were labeled with 
[32P]PO4-3, processed by two- 
dimensional gel electrophore- 
sis, and then transblotted onto 
a  sheet of nitrocellulose.  (,4) 
The location of the hyaluronate 
receptor on the nitrocellulose 
(arrow) was determined by im- 
munostaining  with  the  K-3 
mAb. The positions of various 
standards  of different pI  are 
indicated at the top of the fig- 
ure.  (B)  The presence of 32p 
was  demonstrated  by  autora- 
diography  of  the  nitrocellu- 
lose blot. The arrow indicates 
the presence of label in a loca- 
tion corresponding to the hyal- 
uronate receptor. (Please note 
that  the  autoradiogram  was 
deliberately overexposed to il- 
lustrate more clearly the pro- 
rein of interest.) 
Amicon Corp., Danvers, MA). This sample was mixed with [31-1]H20 (to 
locate the total volume) and applied to a 50 x  1.5-cm column of Sepbarose 
CL-6B and eluted with DOC buffer. The eluted fractions were assayed for 
protein  0BCA; Pierce Chemical Co.) and for [~H]hyaluronate binding ac- 
tivity. For dot blot analysis, alternate  fractions were diluted with 9 vol of 
water and 50/~I aliquots were applied to a sheet of ultrocellulose  using a 
dot blot apparatus  (Bio-Rnd Laboratories).  The sheet was blocked in 5% 
nonfat milk for 1 h and then cut into strips that were incubated individually 
with the various antibodies (4 ~g/rul).  The strips were incubated with the 
appropriate  secondary  probe  (streptavidin  coupled  to peroxidase  for bi- 
otinylated antibodies,  and anti-mouse IgG coupled to peroxidase for non- 
biotinylated  antibodies),  followed by a substrate  consisting of H202 and 
3-amino-9 ethyl carbazole  substrate (11). The reaction was stopped when 
an appropriate  density level was reached. 
Cell Aggregation 
Subconfluent  cultures  of SV-3T3 cells  were  washed  three  times  with 
calcium- and magnesium-free PBS (CMF-PBS) containing 0.02% EDTA. 
The cells were detached from the substratum with a stream of buffer, cen- 
trifuged (300 g, 5 min) and resnspended in a high salt buffer (0.5 M NaCI, 
0.02 M "his, pH 7.3), which optimizes hyaluronate dependent aggregation 
(35).  l-ml aliquots of this cell suspension were added to 20 ml plastic scin- 
tillation vials (Fisher Scientific Co., Columbia, MD) containing the differ- 
ent reagents, and placed on an orbital shaker at I00 rpm. To determine the 
number of single cells and gmail aggregates, 200 ~l of the cell suspension 
was diluted with 20 ml of CMF-PBS and then analyzed with a model Zv 
counter  (Coulter  Electronics  Inc.,  Hialeah,  FL)  (I/amplitude  =  2; 
I/aperture  = 4; window 5-100).  Triplicate readings were taken at 0 and 30 
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in the lymphocyte  binding assays. 
Figure 2. Phosphorylation of 
the hyaluronate receptor. BHK 
cells  were labeled  with [32p]_ 
P04  -3, extracted  in DOC buf- 
fer,  and then the hyaluronate 
receptor was immtmoprecipi- 
tared with the K-3 mAb (41). 
The  immunoprecipitate  was 
then electrophoresed on a 10% 
Na dodecyl sulfate polyacryl- 
amide gel, and blotted onto a 
sheet of nitrocellulose that was 
then  exposed  to  x-ray  film. 
The location of the hyaluron- 
ate  receptor  is  indicated  by 
the arrow on the left and the 
positions of  various molecular 
weight standards are indicated 
on the right. 
rain. The results are expressed in terms of  percent aggregation,  which  corre- 
spends to the following: 
% Aggregation  =  [1  -  (final/initial reading)] x  100. 
Testicular hyaluronidase (10 ~g/nfi; type VI-S; Sigma Chemical Co., St. 
Louis, MO) was added to'one sample to block the hyaluronate dependent 
aggregation. 
Lymphocyte Binding to High Endothelial Cells 
The binding  assay  for lympbocytes  to high endothelial venules  in frozen  sec- 
tions of  peripberal lymph  nodes  and Peyer's  patches has been described pre- 
viously (31, 42). Briefly, mesenteric node lymphocytes  from BALB/c  mice 
or Syrian  hamsters were incubated  in DME with 5 % calf serum and 10 mM 
Hepes with mild rotation at 7°C for 30 rain on unfixed frozen sections of 
BALB/c  peripheral lymph node and Peyer's  patches (2.0 -  3.0 x  106 lym- 
phocytes in 100/zl/section). The slides were fixed in cold PBS containing 
2 % glutaraldehyde. At least three sections containing  multiple lymph  nodes 
or Peyer's  patches were counted for each condition or sample. The results 
are expressed as the number  ofbotmd  lymphocytes  per high endothelial ven- 
ule. It should  be noted  that the binding specificity  of  the lymphocyte  is con- 
served across species barriers (42), thus allowing the use of mouse frozen 
sections for assays with both mouse and hamster lymphocytes. 
In the antibody  blocking  experiments, the mAbs KM-201 and K-3 were 
incubated with lymphocytes  (20 ~g antibody/2 x  106 cells in 100/zl) for 
15 rain at 4°C before  the assay and left with the cells throughout  the assay. 
In other experiments, lymphocytcs  were  preincubated with varying  concen- 
trations of  hyaluronate  (from bovine  vitreous  humor; Sigma  Chemical  Co.) 
for 30 min on ice, and then this mixture was applied to frozen sections to 
assess bindln  S- Controls  were incubated with medium alone. In a separate 
experiment, frozen  sections were  preincubated with hyaluronidase  (type  VI- 
S; Sigma  Chemical  Co.) for 15 rain at room temperature to remove  endoge- 
Results 
Isoelectric Point and Phosphorylation of the 
Hyaluronate Receptor 
In initial experiments,  both the isoelectric point and phos- 
phorylation of the hyaluronate receptor from hamster cells 
were examined. For this, BHK cells were grown in the pres- 
ence of [32P]PO~-3 to label the phosphoproteins and then the 
cells  were  solubilized  in  detergent  and  analyzed  by  two- 
dimensional gel electrophoresis. The resulting gel was blot- 
ted onto nitrocellulose  that was then  stained  for the hyal- 
uronate receptor using the K-3 mAb.  Fig.  1 A  shows that 
the hyaluronate receptor migrated to a  distinct spot in the 
acidic range of the gel. This region corresponded to an iso- 
electric point of approximately 4.0, which is consistent with 
that of the CD44 molecule (18). 
The location of 32p-labeled proteins was then determined 
by exposing the nitrocellulose blot to a  sheet of x-ray film. 
As  shown  in  Fig.  1  B,  the  region  corresponding to  the 
hyaluronate receptor contained a significant amount of  label. 
To further evaluate the presence of  phosphate in this mole- 
cule, extracts of 32p-labeled cells were directly immunopre- 
cipitated with the K-3 mAb and analyzed by SDS-PAGE fol- 
lowed by blotting  onto nitrocellulose.  Autoradiography of 
the blot revealed a prominently labeled band corresponding 
to the hyaluronate receptor (see arrow, Fig. 2), confirming 
the  presence  of  phosphate  in  this  molecule.  Thus,  the 
hyaluronate  receptor  appears  to  be  an  acidic  phospho- 
protein,  as is CD44 (14,  18). 
lmmunoprecipitation of  Hyaluronate-binding  Activity 
by mAbs against CD44 
The  relationship  between  the  hyaluronate  receptor  and 
CD44  was  examined  using  a  panel  of mAbs.  In this  ap- 
proach, aliquots of a detergent extract of cultured cells con- 
taining  the  hyaluronate  receptor  were  incubated  with  bi- 
otinylated mAbs against CD44 (see Table I for a description 
of  each mAb). The mAbs and any specifically bound protein 
were  then  removed  from  the  extract  by  using  immobi- 
lized  streptavidin,  and  the  supernatant  was  assayed  for 
[3H]hyaluronate binding activity. The results of this experi- 
ment are shown in Table II. 
In the case of the hyaluronate receptor from mouse cells, 
neither nonimmune mouse IgG nor the Mel-14 mAb (which 
is  directed  against  a  lymphocyte  receptor  distinct  from 
CD44) were able to immunoprecipitate significant amounts 
of [3H]hyaluronate binding activity.  As a  positive control, 
the K-3 mAb which cross reacts  to some extent with the 
receptor from mouse cells (11, 40) was tested and found to 
remove a  significant fraction of the hyaluronate binding ac- 
tivity.  And  finally,  the  KM-201  mAb  against  the  mouse 
CD44,  was also found to reduce  significantly the level of 
hyaluronate binding activity.  These results  suggest that the 
KM-201  mAb can bind  to  the hyaluronate  receptor  from 
mouse cells. 
When a similar approach was used with the receptor from 
human cells, the K-3 mAb had only a small effect on the level 
of  hyaluronate  binding  activity,  presumably  reflecting  a 
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Source of  Experiment 
receptors  No.  Treatment  Amount  Specific binding  Control 
Mouse 
Human 
lag/ml  cpm 3c range  % 
1  Control IgG  40  2,492 5:121  100 
Mel-14  40  2,871 +  104  115 
K-3  40  1,282 5:45  51 
KM-201  40  614 5:18  25 
1  Control IgG  40  5,735 +  135  100 
K-3  40  5,084 +  104  89 
H2-7  40  2,640 + 301  46 
H2-280  40  1,928 5:21  34 
Hermes-3  40  1,337 5:44  23 
BU52  20  1,722 + 473  30 
J173  40  3,437 5:28  60 
2  Control IgG  40  37,195 4- 61  100 
K-3  40  34,791 5:765  94 
Hermes-1  40  23,393 + 63  63 
The SV-3T3 and HCV-29T cell lines were used as sources of mouse and human ceils, respectively.  The ceils were extracted  in DOC buffer,  preadsorbed  with 
streptavidin-agarose,  and then  incubated  with the various biotinylated  antibodies. After  immunoprecipitation  with streptavidin-agarose,  the supernatants were as- 
sayed for [3H]hyaluronate  binding activity. Batch 1 [3H]hyaluronate  was used in experiments 1 (mouse and human) and batch 2 was used in experiment 2 
(human). 
lower level of cross-reactivity between this antibody and hu- 
man receptor as compared to mouse. However, the mAbs 
directed against human CD44 were able to immunoprecipi- 
tate significant amounts of the receptor as compared to con- 
trol mouse IgG (Table II). 
The hyaluronate binding activity remaining after immuno- 
precipitation could be due to either incomplete removal of 
a homogeneous species or the presence of a heterogenous 
population of receptors, some fraction of which is unable to 
react with the antibodies. To distinguish between these two 
possibilities, an extract was subjected to two rounds of im- 
munoprecipitation with Hermes-3 mAb. Under these condi- 
tions, 90%  of the [3H]hyaluronate binding activity was re- 
moved, suggesting that the receptor is homogeneous with 
respect to its ability to bind to the Hermes-3 mAb. 
The conclusion from this set of experiments is that mAbs 
directed against the CIM4 molecule can immunoprecipitate 
[3H]hyaluronate binding activity from both mouse and hu- 
man  cells,  suggesting  that  the  hyaluronate  receptor and 
CD44 share similar epitopes and that they are closely related 
if not identical molecules. 
Copurification of the Hyaluronate Receptor and CD44 
To evaluate further the relationship between the hyaluronate 
receptor and CD44, the behaviors of these proteins on mo- 
lecular sieve chromatography were compared. For this, the 
receptor was partially purified from the human HCV-29'r 
cells  by  hydroxylapatite  chromatography  and  then  ana- 
lyzed by molecular sieve chromatography on a column of 
Sepharose C1-6B. Fig. 3 shows that the hyaluronate receptor 
elutes with a partition coefficient of 0.4-0.5, consistent with 
that previously reported for the receptor from the mouse SV- 
3T3  cells  (39).  Since the  receptor has  a  highly elliptical 
shape, it behaves as an anomalously large molecular on mo- 
lecular sieve chromatography (39). When the fractions were 
analyzed by dot blot, each of the antibodies to human CD44 
revealed a peak of immunoreactive material eluting with a 
partition coefficient of 0.4-0.5 (Fig. 3; fractions 13 and 15), 
which corresponds to the position of [3H]hyaluronate bind- 
ing activity. Thus, CD44 coelutes from the molecular sieve 
column with the hyaluronate receptor, confirming that these 
proteins are either highly related or identical. 
Unfortunately, a similar approach was not possible with 
the hyaluronate receptor from mouse SV-3T3 cells, since the 
KM-201 mAb did not react with nitrocellulose blots of these 
cells. Presumably, the epitope recognized by the KM-201 is 
not stable to blotting. 
Effect of  Antibodies on the Binding of  Hyaluronate 
The various mAbs were also examined for their ability to 
directly block [3H]hyaluronate binding activity shown (Ta- 
ble Ill). In the case of the receptor from mouse cells, high 
concentrations of Mel-14 (control mAb) had only a modest 
effect on the binding activity, while relatively small amounts 
of the K-3 mAb blocked most of the binding, as had been 
demonstrated previously (11). Likewise, the KM-201 mAb, 
which immunoprecipitated the hyaluronate receptor, also in- 
hibited [3H]hyaluronate binding.  These results suggest that 
the KM-201 mAb recognizes an epitope very close to the 
hyaluronate binding domain on the CIM4 molecule. 
In the case of the receptor from human cells, the K-3 mAb 
as  well  as  the  Hermes-1  mAb  blocked  [3H]hyaluronate 
binding activity, but only at relatively high concentrations. 
However, none of the other mAbs directed against human 
CIM4 had a  significant effect on the binding of [3H]hyal- 
uronate to the receptor. These results suggest that with the 
possible exception of the Hermes-1 mAb, the mAbs against 
human CIM4 appear to be directed to epitopes distinct from 
the hyaluronate binding region of the CD44 molecule. 
Inhibition of  Aggregation by KM-201 
The results of  the previous section indicated that the KM-201 
mAb directly blocked the binding of pH]hyaluronate to the 
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uronate binding activity and CIM4 
immunoreactivity  by  molecular 
sieve chromatography.  The hyal- 
uronate  receptor  from  cultured 
HCV-29T cells was partially pu- 
rified by hydroxylapatite chroma- 
tography  and  then  applied  to  a 
column of Sepharose C1-6B  that 
was eluted with DOC buffer. The 
positions of the void volume (lib) 
and the total volume (Vt) are indi- 
cated.  Each fraction was assayed 
for protein and alternate fractions 
were assayed for [3H]hyaluronate 
(Batch 2) binding activity. Alter- 
hate  fractions  were  also  blotted 
onto  nitrocellulose  and  assayed 
for immunoreactive material with 
the  indicated  mAbs  to  CD44. 
Fractions  13  and  15  contain the 
peak  of [3H]hyaluronate  binding 
activity as well as the maximum 
amount  of imrnunoreactive  ma- 
terial. 
Table lll.Direct Inhibition of  Hyaluronate Binding Activity by mAbs to CD44 
Source of  Experiment 
receptors  No.  Treatment  Amount  Specific binding  Control 
Mouse 
Human 
izg/ml  cpm ± range  % 
1  None (control)  0  5,371  +  647  100 
Mel-14  60  4,453  +  156  83 
K-3  1  2,274  +  129  42 
2  714  +  108  13 
KM-201  1  3,152  +  519  59 
2  829  +  35  15 
1  None (control)  0  10,181  +  207  100 
K-3  20  6,585  +  529  65 
40  3,926  +  280  39 
H2-7  40  12,127  +  1,119  119 
1-12-280  80  8,866  +  639  87 
Hermes-3  140  9,758  ±  486  96 
BU52  40  13,630  +  843  134 
J173  80  8,631  +  164  85 
2  None (control)  0  39,078  +  116  100 
K-3  40  19,270  +  475  49 
Hermes-1  40  19,776  ±  282  51 
80  18,104  +  252  46 
SV-3T3 (mouse) and HCV-29 (human) cells were extracted in DOC buffer, and preincubated with the various antibodies. The extracts were then assayed for 
[31-I]hyaluronate binding activity (Batch 1 was used in experiments i  and Batch 2 in experiment 2). Nonimmune mouse IgG had no effect on the binding, 
The Journal of Cell Biology, Volume t 11,  1990  2770 lO0  •  ,  t  t  , 
8O 
8o 
20 
5  l0  18  ~'0  25 
Antibody Added, ~/rnL 
Figure 4. The effect of the KM-201 mAb on the aggregation  of SV- 
3T3 cells. SV-3T3  cells were suspended in 0.5 M NaCI, 0.02 M Tris, 
pH 7.3, and then swirled in the presence of varying amounts of the 
KM-201 rnAb. After a period of 30 min, the extent of aggregation 
was determined with a counter (Coulter Electronics Inc.). The ini- 
tial counter reading (i.e., time = 0) was 19,809 +  1,405/0.5 ml of 
diluted sample. Each point represents the average of triplicate de- 
terminations and varies by <  10%. The aggregation was totally 
abolished (i.e.,  % aggregation =  0) by the addition of 10 pg/ml 
testicular hyaluronidase. 
receptor on mouse cells. This suggested that this rnAb might 
also be  capable  of preventing hyaluronate dependent ag- 
gregation of mouse cells.  To test this possibility, varying 
amounts of KM-201  were added to suspensions of SV-3T3 
cells. After swirling these cells for 30 min, the extent of 
aggregation was determined with a counter (Coulter Elec- 
tronics Inc.). Fig. 4 shows that relatively small amounts of 
the KM-201 mAb inhibited the hyaluronate dependent aggre- 
gation of the cells. Neither control mouse IgG, nor Mel-14 
had any detectable effect on the extent of aggregation even 
at  much  higher  concentrations  (data  not  shown).  These 
results corroborate the ability of the KM-201  mAb to block 
the binding of hyaluronate to the receptor. 
Hyaluronate Does Not Participate in the Binding of 
Lymphocytes to High Endothelial Venules 
As described above,  the Hermes-3  mAb had no effect on 
hyaluronate binding. Previous studies have shown that this 
mAb  blocks  lymphocyte binding  to  mucosal  endothelial 
cells (17). Taken together, thes  e results suggest that the bind- 
ing of lymphocytes to mucosal endothelial cells involves de- 
terminants on CD44 that are not required for hyaluronate 
binding. However, other studies have shown that polyclonal 
antibodies to  CD44  are  capable  of blocking lymphocyte 
binding not only to mucosal but also to peripheral lymph 
node and synovial high endothelial ceils (3), suggesting that 
additional determinants of CD44, not effected by Hermes-3, 
may also participate in the recognition of endothelial cells. 
Thus, it remained possible that the hyaluronate binding ac- 
tivity of CD44 may also participate in binding to mucosal 
or other high endothelial venules. To test this possibility, the 
binding of lymphocytes to frozen thin sections of high en- 
dothelial venules was examined in the presence and absence 
of  the K-3 and KM-201 mAbs, both of which very effectively 
block the binding of hyaluronate to the receptor. As shown 
in Table IV, neither of these mAbs had a major effect on the 
binding of lymphocytes  to high endothelial venules. The K-3 
rnAb had no detectable effect on the binding of hamster lym- 
phocytes, while the KM-201  rnAb produced only a minor 
reduction in mouse lymphocyte binding to the venules of 
Peyer's patches and did not influence the interaction with 
venules of peripheral lymph node (Table IV). These results 
suggest, but do not prove, that hyaluronate is not involved in 
this adhesion process. 
To evaluate further the possible role of hyaluronate in the 
homing of lymphocytes, the lymphocyte binding assay was 
performed  in  the  presence  of  excess  hyaluronate  and 
hyaluronidase, both of which also inhibit hyaluronate de- 
pendent  adhesion of cells  (35,  37).  Table  V  shows  that 
hyaluronate, even at relatively high concentrations, had only 
a modest effect on the binding of lymphocytes to high en- 
dothelial cells, and this effect may be due to the increased 
viscosity of the medium. Similarly, enzymatic degradation of 
hyaluronate on the frozen sections did not significantly in- 
hibit the binding of lymphocytes (Table V). 
Discussion 
The  results  of  this  and  other  studies  suggest  that  the 
hyaluronate receptor is identical to CD44.  First, both of 
Table IV. Effect of Various mAbs on the Binding of  Mesenteric Node Lymphocytes to High 
Endothelial Venules (HEVs) 
Source of  Experiment 
lymphocytes  No.  Treatment 
Binding of lymphocytes to high endothelial venules 
Peripheral lymph node  Peyer's patches 
Lym/HEV  Control  Lym/HEV  Control 
Hamster 
Mouse 
%  % 
1  Control  10.8  +  1.4  100  6.2  +  0.3  100 
K-3  9.4  5:0.4  87  5.6  5:0.3  90 
1  Control  14.7  5:0.5  100  5.4  5:0.5  100 
K-3  17.9  5:0.8  122  6.5  5:0.6  120 
2  Control  15.6  5:1.7  100  6.4  5:0.5  100 
KM-201  17.0  5:1.0  109  4.6  5:0.5  72 
3  Control  -  -  6.9  5:0.5  100 
KM-201  -  -  5.6  5:0.4  81 
Lymphocytes were prepared from the Peyer's patches of hamsters or mice and preincubated with the indicated mAb at saturating concentrations (20/~g in 100 
td). This mixture was then gently agitated with frozen sections of either peripheral lymph nodes or Peyer's patches from mice. After fixation, the number of lympho- 
cytes bound per high endothelial venule was determined (Lyre/1 ~V). 
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Lymphocytes to High Endothelial Venules (HEVs) 
Treatment  Concentration 
Binding of lymphocytes to high endothelial  venules 
Peripheral  lymph nodes  Peyer's patches 
LytrJHEV  Control  Lym/HEV  Control 
Hyaluronate 
Hyaluronidase 
l~g/ml  %  % 
0  13.6  +  1.1  100  5.5  +  0.6  100 
5  14.4  +  1.1  103  5.2  ±  0.6  95 
50  14.6  ±  1.1  107  5.3  ±  0.6  96 
500  11.0  ±  0.9  81  4.9  ±  0.7  89 
0  10.2  ±  1.1  100  8.6  ±  0.9  100 
1  10.0  ±  1.8  98  7.8  +  1.3  91 
10  13.0  +  2.5  127  8.2  ±  1.1  95 
100  10.6  ±  1.9  104  10.4  ±  1.6  121 
In the first experiment, lymphocytes from mice were preincubated with varying  concentrations  of hyaluronate,  and then assayed for binding to high endothelial 
cell venules in the continued presence of hyaluronata.  After fixation, the number of lymphocytes bound per high endothelial venule was determined (Lym/HEV). 
Results are from a representative  experiment of two performed with similar results. The inhibition  seen at high concentrations  of hyaluronate  is not statistically 
significant. In the second experiment, frozen section of mouse peripheral lymph nodes and Peyer's patches were pretreated with varying amounts of hyaluronidase, 
washed, and then examined in the lymphocyte binding assay. 
these proteins have a very similar type of tissue distribution, 
being present on a number of cell types including macro- 
phages and the actively dividing epithelial cells. Second, the 
hyaluronate receptor is similar to CD44 with respect to mo- 
lecular  weight,  isoelectric  point,  presence  of phosphate 
groups, and behavior on molecular sieve chromatography. 
Third, a number of mAbs directed to CD44 cross react with 
the hyaluronate receptor from both mouse and human cells. 
And fourth, one of these mAbs, KM-201, directly blocks 
the  binding  of hyaluronate to  the  receptor  and  prevents 
hyaluronate-dependent aggregation of cultured mouse cells. 
Several recent studies have provided additional evidence 
for the identity of the hyaluronate receptor and the CD44. 
Lesley et al. (21) have shown that some, but not all, lympho- 
cyte cell lines which express CD44 can bind to dishes coated 
with hyaluronate and that this binding to hyaluronate could 
be blocked by mAbs directed against CD44 (21).  Further- 
more, Aruffo et al. (2) have used the techniques of molecular 
biology to create a  soluble hybrid of CD44 and immuno- 
globulin protein, which was capable of binding specifically 
to  hyaluronate  including  that  associated  with  high  en- 
dothelial cells in culture. Collectively, these observations in- 
dicate that at least some members of the CD44 family of gly- 
coproteins can bind to hyaluronate, and thus are similar or 
identical to the hyaluronate receptor. 
At present it is unclear whether CD44 represents a single 
protein or a series of closely related proteins. This latter pos- 
sibility is suggested by a number of studies. For example, 
Flanagan et al. (6) have shown that two types of CD44 can 
be separated from a single cell type by ion exchange chroma- 
tography. Additionally, Picker et al. (28) have shown that the 
CD44 from squamous epithelia differs from that present on 
lymphocytes, fibroblasts and glial cells with respect to mo- 
lecular weight and isoelectric point. And finally, Lesley et 
al. (21) have found that only a fraction of the cell lines that 
express CD44 can attach to a hyaluronate-coated substra- 
tum. Thus, it is possible that only a subset of the CD44 fam- 
ily of molecules is capable of binding hyaluronate. 
Despite the uncertainty concerning the homogeneity of 
CD44, it is apparent that this protein (or family of proteins) 
is  capable  of binding  to  at least  three  different ligands; 
hyaluronate, collagen types I and VI (4), and the mucosal 
vascular addressin, a protein present on specialized high en- 
dothelial cells that is believed to support lymphocyte  extrava- 
sation in the gut-associated lymphoid tissues (3,  34).  The 
ability of  CD44 to bind to more than one ligand is in keeping 
with it being a member of the cartilage link protein super- 
family of proteins. The link protein itself is capable of bind- 
ing to three ligands; hyaluronate, the cartilage core protein 
and collagen (5). 
The interaction of CD44 with these different ligands ap- 
pears to be responsible for distinct types of cellular adhe- 
sion. For example, the interaction of CD44 with hyaluronate 
has been shown to mediate the divalent cation independent 
aggregation of macrophages and fibroblasts (11). In addition, 
it also appears to be responsible for the binding of some 
types of cultured lymphocytes to stromal cells from bone 
marrow, which can be blocked by the KM-201 mAb (24).  In 
the  present  study,  this  mAb  has  been  shown  to  inhibit 
hyaluronate binding. Indeed, recent experiments have indi- 
cated that in some cases, the adhesion between cultured lym- 
phocytes and stromal cells is specifically inhibited by treat- 
ment with hyaluronidase, confirming the role of hyaluronate 
in this adhesion process (25). 
In contrast, the interaction of CIM4 with hyaluronate does 
not appear to be involved in the binding of lymphocytes to 
high endothelial cells.  Initially, CD44 was believed to be 
responsible for the homing to most lymphoid tissues since 
polyclonal antibodies to CD44 inhibited lymphocyte  binding 
to mucosal, lymph node as well as synovial high endothelial 
cells  07).  However,  subsequent  research  indicated  that 
CD44 was responsible for the selective homing of lympho- 
cytes to the mucosal as opposed to peripheral lymphoid tis- 
sue, since a lymphoid cell line lacking CD44 (Jaukat)  was 
still capable of attaching to endothelial cells of peripheral 
lymph nodes (33). This conclusion was further supported by 
the fact that the mAb Hermes-3 selectively blocked lympho- 
cyte binding to mucosal endothelial cells, but not to periph- 
eral lymph nodes (3).  This mAb also inhibited the interac- 
tion  of  purified  CD44  with  isolated  mucosal  vascular 
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in this tissue (3).  In the present study, the Hermes-3  mAb 
was found to have no effect on the hyaluronate binding activ- 
ity of CD44,  and conversely  mAbs KM-201  and K-3 that 
block hyaluronate binding activity, ~did not substantially in- 
hibit lymphocyte interactions with the high endothelial ven- 
ules of either mucosal or peripheral lymph nodes. Further- 
more,  neither  hyaluronate nor hyaluronidase  inhibited the 
binding of lymphocytes to the venules. Taken together, these 
results  suggest that the  hyaluronate  binding  region  of the 
CD44 molecule is distinct from the Hermes-3 epitope that 
is involved in lymphocyte homing, presumably through its 
interaction with mucosal addressin. This is further supported 
by sequence analysis of CD44 that has revealed that its NH2- 
terminal domain is homologous to the cartilage link protein 
(9, 30), suggesting that the hyaluronate binding site is located 
on the distal region of the molecule.  The Hermes-1  mAb, 
which had some inhibitory effect on the binding of [3H]hyal- 
uronate, recognizes an epitope in this NH2-tcrminal domain 
(our unpublished observations). In contrast, the epitope for 
Hermes-3 appears to be present on a more proximal region 
of the CD44 molecule that is heavily glycosylated  (9). 
It is possible that the CD44 glycoprotein serves a number 
of different  functions  during  the  lifetime  of lymphocytes. 
Through its Hermes-3 epitope, CD44 may help lymphocytes 
to recognize and bind to the high endothelial cells lining the 
venules of mucosal lymphoid tissue. Once the lymphocytes 
have migrated through the endothelial  cells  and enter  the 
connective  tissue,  the  CD44  protein  may  interact  with 
hyaluronate, collagen and potentially other molecules in the 
stroma to allow the lymphocytes to migrate through the ex- 
tracellular matrix. 
In conclusion,  the  apparent  identity  of the hyaluronate 
receptor and CD44 unifies a large body of research concern- 
ing this cell adhesion molecule.  Collectively,  these studies 
yield a detailed picture of the CD44 molecule with respect 
to its interaction  with hyaluronate (36,  39),  addressin (3), 
and collagen (4), its tissue distribution (1, 6,  10, 28, 36), its 
physical properties (6,  18, 39), its amino acid sequence (9, 
30),  carbohydrate component (6),  and its association with 
actin  filaments  (15,  19,  20).  Undoubtedly,  future research 
will reveal additional characteristics for this very interesting 
molecule. 
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